Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K

Targeting the JAK/STAT Signaling Pathway in Breast Cancer: Leaps and Hurdles

Simon Aho1,2,3,4, Clio Coste1,4, Luiza Purcari1,4

  • 1Université de Lyon, F-69000 Lyon, France.

Biomedicines
|December 30, 2025
PubMed

Insights

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is crucial for cell functions but its dysregulation drives cancer. Understanding JAK/STAT signaling in breast cancer is key to developing effective therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The JAK/STAT signaling pathway regulates critical cellular processes like immunity, proliferation, and apoptosis.
  • Dysregulation of this pathway is a hallmark of tumorigenesis, particularly in hematological malignancies.
  • Emerging evidence implicates JAK/STAT signaling in the development of solid tumors, including breast cancer.

Purpose of the Study:

  • To review current therapeutic strategies targeting the JAK/STAT pathway in clinical trials.
  • To explore the role of JAK2 in breast cancer, especially in endocrine therapy resistance.
  • To provide perspectives for future research on JAK/STAT signaling in breast cancer.

Main Methods:

  • Exhaustive literature review of clinical trials targeting JAK/STAT pathway components.
  • Analysis of existing data on JAK/STAT pathway involvement in breast cancer.
  • Exploration of JAK2's role in endocrine therapy resistance mechanisms.

Main Results:

  • Clinical trials targeting JAK/STAT signaling in cancer have shown disappointing results.
  • A deeper understanding of the JAK/STAT pathway in breast cancer is needed.
  • JAK2 may play a significant role in resistance to endocrine therapy in hormone-dependent breast cancers.

Conclusions:

  • Despite its central role, targeting the JAK/STAT pathway in breast cancer requires further investigation.
  • Future research should focus on elucidating JAK2's specific functions in breast cancer and endocrine resistance.
  • Novel therapeutic approaches may emerge from a comprehensive understanding of this pathway.
Keywords:
JAKSTATbreast cancerinhibitorssignaling

More Related Videos

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

4.1K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.1K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K